Mechanisms of CPT1C-Dependent AMPAR trafficking enhancement by Gratacòs i Batlle, Esther et al.
ORIGINAL RESEARCH
published: 08 August 2018
doi: 10.3389/fnmol.2018.00275
Mechanisms of CPT1C-Dependent
AMPAR Trafficking Enhancement
Esther Gratacòs-Batlle1,2†, Mireia Olivella3†, Nuria Sánchez-Fernández1†,
Natalia Yefimenko4, Federico Miguez-Cabello1, Rut Fadó5,6, Núria Casals 5,6,
Xavier Gasull1,2, Santiago Ambrosio7,8 and David Soto1,2*
1Laboratori de Neurofisiologia, Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de
Neurociències, Universitat de Barcelona, Barcelona, Spain, 2Institut d’Investigacions Biomèdiques August Pi i Sunyer
(IDIBAPS), Barcelona, Spain, 3Grup de Recerca en Bioinformàtica i Estadística Mèdica, Universitat de Vic, Barcelona, Spain,
4Laboratori de Neurobiologia, Department de Patologia i Terapèutica Experimental, Facultat de Medicina i Ciències de la
Salut, Campus Universitari de Bellvitge, Universitat de Barcelona, Barcelona, Spain, 5Department de Ciències Bàsiques,
Facultat de Medicina i Ciències de la Salut, Universitat Internacional de Catalunya, Barcelona, Spain, 6Centro de
Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III,
Barcelona, Spain, 7Unitat de Bioquímica, Departament de Ciències Fisiològiques, Facultat de Medicina i Ciències de la Salut,
Campus Universitari de Bellvitge, Universitat de Barcelona, Barcelona, Spain, 8Institut d’Investigacions Biomèdiques de
Bellvitge (IDIBELL), Barcelona, Spain
Edited by:
Rolf Sprengel,
Max-Planck-Institut für Medizinische
Forschung, Germany
Reviewed by:
Ana Luisa Carvalho,
University of Coimbra, Portugal
Ingo H. Greger,
MRC Laboratory of Molecular Biology
(MRC), United Kingdom
*Correspondence:
David Soto
davidsoto@ub.edu
†These authors have contributed
equally to this work
Received: 14 March 2018
Accepted: 20 July 2018
Published: 08 August 2018
Citation:
Gratacòs-Batlle E, Olivella M,
Sánchez-Fernández N, Yefimenko N,
Miguez-Cabello F, Fadó R, Casals N,
Gasull X, Ambrosio S and Soto D
(2018) Mechanisms of
CPT1C-Dependent AMPAR
Trafficking Enhancement.
Front. Mol. Neurosci. 11:275.
doi: 10.3389/fnmol.2018.00275
In neurons, AMPA receptor (AMPAR) function depends essentially on their constituent
components: the ion channel forming subunits and ion channel associated proteins.
On the other hand, AMPAR trafficking is tightly regulated by a vast number of intracellular
neuronal proteins that bind to AMPAR subunits. It has been recently shown that the
interaction between the GluA1 subunit of AMPARs and carnitine palmitoyltransferase
1C (CPT1C), a novel protein partner of AMPARs, is important in modulating surface
expression of these ionotropic glutamate receptors. Indeed, synaptic transmission in
CPT1C knockout (KO) mice is diminished supporting a positive trafficking role for that
protein. However, the molecular mechanisms of such modulation remain unknown
although a putative role of CPT1C in depalmitoylating GluA1 has been hypothesized.
Here, we explore that possibility and show that CPT1C effect on AMPARs is likely due
to changes in the palmitoylation state of GluA1. Based on in silico analysis, Ser 252,
His 470 and Asp 474 are predicted to be the catalytic triad responsible for CPT1C
palmitoyl thioesterase (PTE) activity. When these residues are mutated or when PTE
activity is inhibited, the CPT1C effect on AMPAR trafficking is abolished, validating
the CPT1C catalytic triad as being responsible for PTE activity on AMPAR. Moreover,
the histidine residue (His 470) of CPT1C is crucial for the increase in GluA1 surface
expression in neurons and the H470A mutation impairs the depalmitoylating catalytic
activity of CPT1C. Finally, we show that CPT1C effect seems to be specific for this
CPT1 isoform and it takes place solely at endoplasmic reticulum (ER). This work adds
another facet to the impressive degree of molecular mechanisms regulating AMPAR
physiology.
Keywords: AMPARs, CPT1C, surface expression, current density, palmitoylation, AMPAR trafficking, hippocampal
pyramidal neurons
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INTRODUCTION
Amongst ionotropic glutamate receptors, α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptors
(AMPARs) are considered the ‘‘work-horses’’ of fast excitatory
neurotransmission in the brain since they mediate nearly 90% of
synaptic transmission. AMPARs are homo- or heterotetrameric
structures, in which four different types of subunits (GluA1,
2, 3 and 4) form the basic core of the receptor by making
a cationic pore mainly permeable to Na+ and K+ ions but
also Ca2+ ions in GluA2-lacking AMPARs (Traynelis et al.,
2010). Essentially, the presence or absence within the receptor
of a given AMPAR subunit is an important determinant of
its properties, which will finally translate into differential
integration of the signals at postsynaptic sites. Additionally,
AMPAR function in neurons is finely regulated by a noticeable
array of interacting proteins, which determine their biophysical
properties and govern their intracellular trafficking, exocytosis,
endocytosis and synaptic targeting. Actually, in the last decade,
the AMPAR field has experienced a fascinating step forward
due to the discovery of AMPAR auxiliary subunits, which are
important modulators of AMPAR function (Yan and Tomita,
2012; Greger et al., 2017). There are several transmembrane
proteins belonging to different families that have been described
to command AMPAR function: transmembrane AMPAR
regulatory proteins (TARPs), Cornichon homologs (CNIHs),
Cystine-knot AMPAR modulating proteins (CKAMPs) and the
more recently discovered GSG1L protein (Straub and Tomita,
2012; Farrow et al., 2015; McGee et al., 2015).
Some recent proteomic studies performed in brain extracts
confirmed the physical interaction of GluA subunits with
these previously mentioned auxiliary proteins and interestingly
revealed several new partners of AMPARs (Schwenk et al.,
2012, 2014). Amongst the newly identified proteins, carnitine
palmitoyltransferase 1C (CPT1C) was shown later to be
important in AMPAR function (Gratacòs-Batlle et al., 2015;
Fadó et al., 2015). Specifically, GluA1-containing AMPARs
were trafficked more efficiently to the plasma membrane by
CPT1C (Gratacòs-Batlle et al., 2015) and the absence of this
protein in CPT1C knockout (KO) animals was translated into a
decrease in miniature excitatory postsynaptic currents (mEPSCs)
in hippocampal neurons (HPNs) in culture (Fadó et al.,
2015). Furthermore, EPSCs in mossy cells from hippocampal
slices were diminished after CPT1C knockdown with short
hairpin RNAs (Brechet et al., 2017). Another member of the
CPT1 family, CPT1A, has been described not to increase
GluA1-mediated currents (Gratacòs-Batlle et al., 2015). This
suggests that the mechanism of traffic enhancement is unique
to CPT1C. CPT1C also seems to be involved in the synthesis
of GluA1 acting as a regulator of AMPAR levels (Fadó et al.,
2015) and it has been recently published that CPT1C forms
part of specific TARPless AMPAR complexes present in the
endoplasmic reticulum (ER) where it has been suggested
to prepare—together with Ferric Chelate Reductase 1 like
(FRRS1L) as a priming complex—AMPARs for further assembly
with TARPs and CNIHs to allow receptors to exit the ER
(Brechet et al., 2017). Despite the evident relevance of CPT1C
in AMPAR trafficking, the molecular events leading to an
enhancement of GluA1 surface expression have not been
unraveled.
CPT1C, together with CPT1A and CPT1B belongs to the
family of carnitine long-chain acyltransferases (Casals et al., 2016;
CPT1s). While CPT1A and CPT1B are localized in the outer
membrane of mitochondria (Broadway et al., 2003), CPT1C is
located in the ER of neurons (Sierra et al., 2008; Carrasco et al.,
2012), which suggests a functional difference between CPT1C
and the other members of the family. CPT1A and CPT1B are
composed of a small N-terminal domain and a large catalytic
C-terminal domain, separated by two transmembrane domains
and a short connecting loop with both N and C terminal
regions exposed to the cytosolic side of the mitochondrial
membrane (Fraser et al., 1997). No crystal structures are available
for CPT1 enzymes, but there is for other members of the
acyltransferase family (Wu et al., 2003). CPT1s catalyze the
exchange of acyl groups between CoA and carnitine to facilitate
the transport of long chain fatty acids from the cytoplasm to
the mitochondria for β-oxidation (McGarry and Brown, 1997).
CPT1A and CPT1B have a catalytic histidine 473, which turns
out to be crucial for CPT1s enzymatic reaction (Morillas et al.,
2001). This residue is also conserved in CPT1C (His 470) and
despite the fact that CPT1C binds to palmitoyl-CoA as CPT1A
and CPT1B, its CPT1 catalytic activity is 100-fold lower than
other CPT1s (Sierra et al., 2008). This low catalytic activity has
been long considered residual but could indeed indicate that
CPT1C presents differences in its catalytic function compared to
other CPT1s.
The palmitoylation state of AMPARs is important for
their delivery to plasma membrane in neurons (Hayashi
et al., 2005). Specifically, depalmitoylation of cysteine 585 in
GluA1 favors trafficking to the plasmamembrane.We previously
demonstrated that CPT1C enhancement of GluA1-containing
AMPARs surface expression is dependent on the palmitoylable
residue cysteine 585 (Gratacòs-Batlle et al., 2015) suggesting
that changes in the palmitoylation state of GluA1 mediated
by CPT1C might be responsible for this effect. However, no
depalmitoylation activity has been demonstrated for CPT1C.
Indeed, one of the best studied depalmitoylating enzymes is
the acyl protein thioesterase 1 (APT1), a cytosolic enzyme
that catalyzes depalmitoylation of membrane anchored proteins
(Zeidman et al., 2009; Salaun et al., 2010) through the catalytic
Ser 119, Asp 174 and His 208 triad in human APT1 sequence
(Devedjiev et al., 2000; Wang et al., 1997).
In the present study, we have focused on unraveling the
molecular mechanism underlying CPT1C-mediated AMPAR
modulation. Combining in silico and experimental approaches
we have identified Ser 252-His 470-Asp 474 as the catalytic triad
in CPT1C involved in depalmitoylating activity. Mutagenesis
studies of these key residues abolished CPT1C effect on
AMPAR trafficking. In addition, inhibition of CPT1C activity
by Palmostatin-B (PB), an inhibitor of palmitoyl thioesterase
(PTE) activity in APT1 (Dekker et al., 2010), impedes CPT1C
modulation of GluA1-mediated AMPAR currents. Thus, we
propose that CPT1C modulates AMPAR trafficking through
depalmitoylation of GluA1.
Frontiers in Molecular Neuroscience | www.frontiersin.org 2 August 2018 | Volume 11 | Article 275
Gratacòs-Batlle et al. AMPAR Modulation by CPT1C
MATERIALS AND METHODS
CPT1C Computational Molecular Model
In Silico CPT1C Molecular Model
An initial homology model was constructed for the catalytic
domain of human CPT1C using the coordinates of the
determined X-ray crystal structure of human carnitine
acetyltransferase (PDB ID: 1NM8, 1.8 Å of resolution, 30%
of sequence identity; Wu et al., 2003). Modeller 9.12 (Sali and
Blundell, 1993) was used to model the non-determined regions.
The side chain conformations for non-conserved residues were
positioned according to Scwrl 4 (Krivov et al., 2009). The protein
was embedded in a tip3p water box. The initial system was
energy minimized, subjected to 10 ns of molecular dynamics
equilibration and finally to a production stage extending to
150 ns. All the simulations were performed with GROMACS
5.0 simulation package (Berendsen et al., 1995).
The relative disposition of residues Ser114, Asp169 and
His203 that constitute the catalytic triad in human APT1 (PDB
ID: 1FJ2, 1.5 Å; Devedjiev et al., 2000) were used to identify
the putative serine and aspartate residues that together with His
470 constitute the catalytic triad in human CPT1C. Structural
superimposition of human CPT1C molecular model to human
APT1 structure with PyMOL (PyMOL) identified Ser 252 and
Asp 474 as the two residues that together with His 470 constitute
the catalytic triad.
CPT1C—CoA—Carnitine—Palmitate
The position of carnitine and CoA in the binding pocket
was obtained by structurally superimposing the structure of
murine carnitine acetyl-transferase in complex with acetyl-CoA
and carnitine (PDB ID: 2H3U, 1.9 Å) to human CPT1C
molecular model with PYMOL (PyMOL) resulting in 0.445
Å of root mean square deviation (RMSD). In order to
obtain the position of palmitate, the structure of rat carnitine
palmitoyltransferase II (PDB ID: 4EP9, 2.03 Å) was structurally
superimposed to a CPT1C molecular model with PYMOL
(PyMOL), resulting in 1.106 Å of RMSD. The final structure of
CPT1C in complex with CoA, carnitine and palmitate was energy
minimized.
Animals and Housing
C57BL/6J Wild-type (WT) and CPT1C KO mice (MGI
database ID: 5432790) were provided by the laboratory of
Dr. Núria Casals (Universitat Internacional de Catalunya)
and were obtained as described in Carrasco et al. (2012).
Animals were housed in cages with free access to food
and water and were maintained under controlled day–night
cycles in accordance with the NIH Guide for the Care and
Use of Laboratory Animals, the European Union Directive
(2010/63/EU), and the Spanish regulations on the protection
of animals used for research, following a protocol approved
and supervised by the CEEA-UB (Ethical Committee for
Animal Research) from University of Barcelona with the
license number OB117/16, of which DS is the responsible
researcher.
Cell Lines Culture and Transfection
HEK293-AD, COS-7 and tsA201 cell lines were used in
this study. tsA201—or HEK293T—are HEK293 cells that
constitutively express the SV40 large T antigen to allow plasmid
replication using the SV40 origin and hence to produce high
levels of recombinant proteins (Sigma catalog 85120602). Cells
were maintained as described in Gratacòs-Batlle et al. (2015).
Cells were transiently co-transfected with 5.4 µg total cDNA
(for Co-IP) and 0.6 µg total cDNA (for immunofluorescence,
IF and electrophysiology) using PEI transfection reagent
(1 mg/ml) in a 3:1 ratio (PEI:DNA). In all transfections
the DNA ratio used was 1:2 (GluA:CPT1C). Media was
replaced 3–5 h after transfection with fresh media containing
2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo [f]quinoxaline-7-
sulfonamide at 50 µM (NBQX; Tocris-ABCam) to prevent
excessive AMPAR-mediated toxicity. For electrophysiology
experiments, cells were re-plated on coated glass coverslips to
allow optimal density. All experiments were performed 48 h after
transfection.
Hippocampal Neuronal Cultures and
Transfection
Hippocampal neuronal cultures were performed from P0 to P2
(aged 0–2 days)WT or CPT1C-KOC57BL/6J mice in accordance
with Catalan animal procedures (Decret 214/97; Generalitat de
Catalunya) as described in Coombs and Soto (2016). Briefly,
hippocampi were isolated and maintained in precooled Hank’s
Balanced Salt Solution (HBSS, Gibco) supplemented with 0.45%
glucose. Hippocampi were chopped and chemically digested with
Trypsin (Type XI; Sigma). After two washes of the tissue with
pre-warmed HBSS, a mechanical digestion was performed in
plating media by passing hippocampal tissue through decreasing
tip diameter sigmacoated glass Pasteur pipettes to achieve a single
cell suspension. The dissociated cell suspension was carefully
placed on top of a pre-warmed ovomucoid-BSA solution
(10 mg/ml in HBSS for each) and centrifuged (1,000× g) during
10 min. The resulting pellet was resuspended in platting media
(Coombs and Soto) and seeded on poly-D-Lysine/laminin-
coated 12 mm ∅ coverslips (VWR International) into 24-well
plates at a density of 100,000–150,000 cells/well. AraC (Sigma)
was added at 2 days in vitro (d.i.v.) at a concentration of 5 µM.
2/3 of fresh maintenance media containing AraC was changed
every 4–5 days.
Neuronal cultures were transiently transfected with
0.8 µg total cDNA for both IF and electrophysiology using
Lipofectaminer 2000 (Invitrogen) following manufacturers
indications. Media was replaced 4 h after transfection with
conditioned medium. All experiments were performed between
48 h and 72 h after transfection.
Expression Constructs
To obtain CPT1C-EGFP (referred hereafter as CPT1C-GFP or
CPT1C) cDNAs with mutations in the putative thioesterase
catalytic residues, we used site-directed mutagenesis to change
specific base pairs. Primers containing the desired mutation were
designed and obtained at Sigma-Aldrich.
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CPT1C(H470A) and CPT1C-(S252A, H470A, D474A)
mutant cDNAs resulted from changing codons: CAC to GCC,
GAC to GCC and AGC to GCC respectively and sequentially
for the triple mutant. All changes produce an alanine instead of
the potentially active residue as has been performed previously
for mutating the catalytic triad of many thioesterases (Devedjiev
et al., 2000; Tian et al., 2012; Yokoi et al., 2016). The primers
used for introducing the mutations were the following:
CPT1C-S252A: ggctcgctggttaatGCcacctactacatgatgg
CPT1C-H470A: ctcagcgtggagGCctcatgggctgactgc
CPT1C-D474A: ggcctcatgggctgCctgccctgtcgcggg
All constructs were fully sequenced to verify sequence
integrity.
AMPAR subunit cDNAs were a gift from S. Heinemann
(Salk Institute, La Jolla, CA, USA) and P. Seeburg (Max
Planck Institute, Heidelberg, Germany). DHHC-3/GODZ
expression vector was a gift from Luke Chamberlain (Strathclyde
University). pDs-Red-ER-KDEL and pGFP-Sec61B constructs
were a gift from Juan Pablo Muñoz (IRB, Barcelona). The
characteristics of CPT1C and CPT1A plasmid vectors were
described in Gratacòs-Batlle et al. (2015). Plasmid constructs for
the expression of chimeric proteins C-CPT1A and A-CPT1C
where obtained as described in Sierra et al. (2008). All plasmid
vectors are under the control of CMV promoter.
Coimmunoprecipitation
Coimmunoprecipitation From tsA201 Cells
Forty-eight hours after transfection, tsA201 cells grown in T-25
flasks were washed twice with room temperature (RT) PBS and
scraped with ice-cold lysis buffer (1% Triton TX-100, 50 mM
Tris-HCl pH 8, 150 mM NaCl, Protease Inhibitor Cocktail
(Roche) and PMSF). All subsequent steps were performed at
4◦C. Cells were lysed with a 30 G syringe six times and
membranes were solubilized during 30 min in an orbital agitator.
Insoluble material was pelleted at 16,000× g for 30 min. Protein
concentration in the supernatant was quantified by the BCA
method and 0.4–1 mg of protein was incubated overnight with
2–4 µg of anti-GluA1-NT (MerckMillipore) or with anti-GFP
antibody (rabbit serum from Life Technologies) with orbital
agitation. Antibody-protein complexes were pulled down by
incubating with 80–100 µl of Protein-A sepharose beads (Sigma)
for 2–3 h. Precipitated complexes were washed with lysis buffer
three times and eluted with 2× SB/5 mM DTT sample buffer,
heated 10 min at 76◦C and separated by SDS/PAGE. Before
adding the antibodies, 10% of total protein was removed as input
samples and boiled at 75◦C for 10 min in 2× SB/5 mM DTT.
Coimmunoprecipitation From Mouse Brain
Hippocampi, cerebellums and frontal cortices were obtained
from C57BL/6J WT and CPT1C KO mice of 1 or 2 months
of age. After dissection, they were sonicated in cold Tris·HCl
pH 7.4 (with Protease Inhibitor Cocktail (Roche) and PMSF)
with a Broanson Sonifier 150 (5 watts). All subsequent steps
were performed at 4◦C. The homogenate was centrifuged at
16, 000 xg for 30 min at 4◦C. The pellet was resuspended by
pipetting up and down in ice-cold lysis buffer (1% IGEPAL,
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% Glycerol, Protease
Inhibitor Cocktail (Roche) and PMSF) and solubilized during
30 min in an orbital agitator. Insoluble material was pelleted at
16,000× g for 30 min. Protein concentration in the supernatant
was quantified by the BCA method and 1.5 mg of protein
were incubated overnight with 2 µg of anti-GluA1 antibody
with orbital agitation. Antibody-protein complexes and inputs
were obtained as described in coimmunoprecipitation from
tsA201 cells.
Immunoblotting
Samples were separated in 8% mini-protean SDS/PAGE gels,
transferred using Trans-Blot Turbo transfer system on PVDF
membranes (all from BioRad). Membranes were blocked in
TBS with 0.1% Tween 20 (TBS-T) containing 3% (wt/vol)
BSA. Primary antibodies used to detect different proteins were
the same described for immunoprecipitations and anti-CPT1C
(RRID:AB_2636893, Sierra et al., 2008; Pozo et al., 2017).
Peroxidase-conjugated goat anti-mouse or goat anti-rabbit
secondary antibodies diluted in blocking solution, were detected
by using WesternBright ECL (Advansta) and exposed to light-
sensitive film (Amersham Hyperfilm).
Immunofluorescence
IF was performed in tsA201 cells and neuronal cultures grown
on lysine treated coverslips (plus laminin for neurons), 48 h
after transfections. Washes were performed by immersion of
the coverslips in PBS with Calcium and Magnesium (PBS-
CM) or PBS-G (20 mM Glycine in PBS-CM). Composition of
solutions were as follows: fixation solution (4% PFA in PBS),
permeabilization solution (0.1% Triton X-100 in PBS-G −0.3%
for neurons), blocking solution (10% NGS, 2% BSA, 0.1% Triton
X-100 in PBS-G), antibody incubation solution (4% normal goat
serum and 0.1% BSA in PBS-G) and triton-antibody solution
(antibody incubation solution containing 0.1% Triton X-100).
Incubations with antibodies were performed in a humid chamber
at 37◦C for 1 h.
Surface staining of AMPARs was achieved by labeling live
cells with the mouse anti-GluA1-NT (from Merck Millipore)
in a 1:500 solution in DMEM:F12, for 10 min at 37◦C for
cell lines or in a 1:500 solution in Neurobasal/B27, for 1 h at
37◦C for neurons. After six washes in RT PBS-CM, cells were
fixed for 15 min at RT and incubated with goat anti-mouse
Alexafluor 555 (Molecular Probes) diluted 1:500 in antibody
incubation solution. After several washes in PBS-CM, cells
were fixed again to preserve the binding of the first secondary
antibody. Cells were subsequently permeabilized for 5–10 min
and blocked for 30 min. Next, and in order to determine the
intracellular expression of AMPARs in each cell, GluA1 were
labeled, incubating the coverslips with the same mouse anti-
GluA1-NT antibody at 1:500 (in triton-antibody incubation
solution). Following washes in PBS-CM, cells were incubated
with goat anti-mouse Alexafluor 647 (Molecular Probes) at 1:500
(in triton-antibody incubation solution). Coverslips were then
washed and mounted with Mowiol (Calbiochem).
For co-localization of A-CPT1C or C-CPT1A, the following
method was used: COS-7 cells were transfected with the different
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CPT1-GFP tagged plasmid constructs with or without an ER
marker (200 ng of RE-KDEL-dsRed tagged). For co-localization
with a mitochondrial marker, transfected cells were incubated
with MitoTracker (Thermo Fisher Scientific) at 25 nM during
20 min at 37◦C. Cells were washed in PBS, fixed in 4% PFA for
15 min and mounted in Fluoromount.
For co-localization of CPT1C with a COPII marker (mouse
Sec31A, BD Biosciences), COS-7 cells were transfected with
200 ng of CPT1C-GFP or with pGFP-Sec61B plasmid. Forty-
eight hours after transfection cells were fixed for 15 min in
4% PFA, washed and IF against Sec31A (1:100) with Alexafluor
555 antimouse at 1:500 (Molecular Probes) was performed.
Confocal Imaging and
Immunofluorescence Quantification
Confocal images were acquired with a Leica TCS SP5 laser
scanning confocal microscope (Leica Microsystems Heidelberg
GmbH,Manheim, Germany) equipped with a DMI6000 inverted
microscope, blue diode (405 nm), Argon (458/476/488/496/514),
diode pumped solid state (561 nm) and HeNe (594/633 nm)
lasers and a PLAN APO 63× oil (NA 1.4) immersion objective
lens. DAPI, GFP, Alexa Fluor 555 and Alexa Fluor 647 images
were acquired sequentially using 405, 458, 488, 561 and 633 laser
lines, AOBS (Acoustic Optical Beam Splitter) as beam splitter and
emission detection ranges 415–480, 500–550 nm, 571–625 and
643–680 nm respectively and the confocal pinhole set at 1 Airy
units. Images were acquired at 600 Hz in a 1024 × 1024 pixels
format, zoom at 1 and pixel size of 240.3× 240.3 nm, for imaging
tsA201 and zoom at 3 with a pixel size of 80.2 × 80.2 nm for
neurons.
IFs quantification was performed as described in Gratacòs-
Batlle et al. (2015) using ImageJ (NIH). A set of three different IF
images for each condition were performed and 30–80 cells from
each condition were analyzed for each IF. For cortical and HPNs
images were taken from 3 to 5 different cultures. Quantification
of co-localization was performed using the Manders’ Overlap
coefficient (MOC) calculated in ImageJ via the JACoP plugin
from images of single cells. This coefficient ranges between 1 and
zero with 1 being high co-localization, zero being low.
Electrophysiology: Whole-Cell Recordings
on tsA201 Cells and Hippocampal Neurons
Whole-cell recordings were performed from isolated transfected
cells visualized with an inverted epifluorescence microscope
(Axio-Vert.A1; Zeiss). Thick-walled electrodes were fabricated
from borosilicate glass (1.50 mm O.D., 1.16 mm I.D., Harvard
Apparatus) pulled with a P-97 horizontal puller (Sutter
Instruments) with a final electrode resistance of 3–5 MΩ. In
tsA201 transfected cells, macroscopic currents were activated
from GFP-positive cells by a bath application of 1 mM glutamate
plus 25 µM cyclothiazide to prevent receptor desensitization and
were recorded by applying a voltage ramp protocol from –80 mV
to +80 mV at a rate of 160 mV/s) as previously described in
Gratacòs-Batlle et al. (2015). In pyramidal HPNs currents were
activated by a 20 s rapid piezo-driven application of 20 µM
AMPA +10 µM cyclothiazide. In both types of recordings, to
avoid errors due to differences in cell surface area, the responses
were expressed as current density (–pA/pF; current at –80 mV
(tsA201 cells) or –60 mV (HPNs) divided by input capacitance).
Currents were recorded with Axopatch 200B amplifier, filtered
at 2 kHz and digitized at 5 kHz using Digidata 1440A interface
with pClamp 10.2 software (Molecular Devices Corporation).
For tsA201 cell recordings the ‘‘extracellular’’ solution contained
(in mM): 145 NaCl, 2.5 KCl, 1 CaCl2, 1 MgCl2, 10 glucose and
10 HEPES (pH to 7.42 with NaOH). The ‘‘intracellular’’ solution
contained (in mM): 145 CsCl, 2.5 NaCl, 1 Cs-EGTA, 4 MgATP
and 10 HEPES (pH = 7.2 with CsOH). For HPNs recordings the
‘‘extracellular’’ solution contained (in mM): 140 NaCl, 3.5 KCl,
1.8 CaCl2, 0.8 MgCl2, 20 glucose and 10 HEPES (pH to 7.42 with
NaOH). The ‘‘intracellular’’ solution contained (in mM): 116 K-
gluconate, 6 KCl, 8 NaCl, 0.2 EGTA, 2 MgATP, 0.3 NaGTP and
10 HEPES (pH = 7.2 with KOH). TTX 1 µM was added to
block synaptic transmission. The specific blockers of NMDARs
and GABAARs, APV 25 µM and picrotoxin 100 µM were
present to minimize background noise due to spontaneous
release of neurotransmitters. All recordings were obtained for
at least three different hippocampal neuronal cultures. Spermine
tetrahydrochloride (Sigma Aldrich) was added to intracellular
solution at 100 µM in all electrophysiology experiments.
Acyl-Biotin Exchange Assay (ABE)
Detection of palmitoylation levels of GluA1 subunits was
performed exactly as described in Brigidi and Bamji (2013).
HEK293-AD cells stably expressing GluA1 were transfected
with 2 µg of GODZ (pEF-BOS-HA-DHHC3) and 4 µg of
GFP, CPT1C-GFP or CPT1C(H470A)-GFP cDNA’s. Forty-eight
hours after transfection, cells were washed twice with RT PBS
with Calcium andMagnesium and scraped in ice-cold lysis buffer
(LB: 1% IGEPAL, 50 mM Tris-HCl pH 7.5, 150 mM NaCl,
10% Glycerol, Protease Inhibitor Cocktail (Roche) and PMSF)
containing 50 mM N-ethylmaleimide NEM (Sigma). Then, cells
were lysed with a 30 G syringe six times and incubated 20 min
with orbital agitation at 4◦C. All steps where performed at 4◦C.
Lysates were cleared by centrifugation at 16,000× g for 30 min
and the amount of protein in the supernatant was determined
using the BCA method (Thermo Scientific). 750 µg–1.5 mg of
protein were used for overnight immunoprecipitation of GluA1
(4 µg of anti-GluA1-NT antibody (Merck Millipore)). Then,
protein-antibody complexes were pulled-down with Protein-A
sepharose beads (Sigma) preequilibrated with LB/50 mM NEM
for 1.5 h. The total immunoprecipitate was then resuspended
in LB with 10 mM NEM and was split into two equivalent
samples: one sample for specific cleavage and unmasking of
the palmitoylated cysteine’s thiol group by 1 M hydroxylamine
treatment (+HAM sample) and a second equivalent sample in the
absence of HAM to control non-specific incorporation of biotin
(−HAM sample). Before performing HAM treatment, samples
were washed extensively to remove unbound NEM (one rapid
wash with Stringent buffer (LB/10 mM NEM and 0.1% SDS)
and three washes with LB (pH 7.2)). 1 M HAM solution was
prepared in pH 7.2 LB and ±HAM treatment was performed
with rotation for 1 h at RT. After one wash in LB pH 6.2,
selective labeling of the basal palmitoylated cysteines (which after
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HAM treatment becomes a cysteine with a free-thiol group)
using a thiol-reactive biotinylation reagent, biotin-BMCC (1µM;
Thermo Scientific) in pH 6.2 LB was performed for 1 h at
4◦C with orbital agitation in ±HAM samples. Afterwards, the
thiol-biotinylated proteins following the acyl-biotin exchange
assay (ABE) steps were washed three times in LB (pH 7.5) and
resolved by SDS-PAGE and Western Blotting was performed.
Membranes were blocked with 3% BSA in TBS-T and incubated
with Streptavidin-HRP (Invitrogen; 1:5,000 from a 1 mg/ml
stock in 0.3% BSA). After stripping (Thermo Fisher Stripping
buffer), the same membrane was incubated with an anti-GluA1-
NT antibody (1:2,000) to normalize palmitoylation levels to the
amount of immunoprecipitated protein.
Western Bright ECL (Advansta) was applied on blotting
membrane for protein detection. Images were captured using
Chemidoc Digital Imaging system (BioRad) and analyzed with
ImageLab 6.0 software (BioRad).
Analysis and Statistics
Electrophysiological recordings were analyzed using IGOR
Pro (Wavemetrics Inc.) with NeuroMatic (Jason Rothman,
UCL). Data are presented in the text as the mean ± SEM
from n experiments and in the figures as bar plots of the
group mean, with error bars denoting the SEM. Comparisons
between two groups were performed using the non-parametric
Mann-Whitney U test. Differences were considered significant
at p < 0.05. Statistical analysis was performed using GraphPad
Prism version 5.0d for Mac OS X (GraphPad Software, San
Diego, CA, USA1).
RESULTS
GluA1 and CPT1C Coimmunoprecipitate in
Different Brain Areas
CPT1C protein has been shown to play an important role
in GluA1-containing AMPAR surface expression including
GluA1/GluA2 heteromers (Gratacòs-Batlle et al., 2015). In
HPNs GluA1/GluA2 is the dominant AMPAR arrangement
(Pellegrini-Giampietro et al., 1994; Gold et al., 1996; Sans et al.,
2003) and in CPT1C KO animals the number of AMPARs
at hippocampal neuron synapses seems to be reduced (Fadó
et al., 2015). Since GluA1 is also importantly expressed in other
brain areas, we first decided to study the ability of CPT1C
to interact with GluA1 subunits in different brain tissues.
Thus, we performed coimmunoprecipitation assays from cortex,
cerebellum and hippocampus of WT and CPT1C KO animals
(P24–39). Anti-GluA1 antibody clearly pulled down CPT1C
from cortex, cerebellum and hippocampus (Figure 1A, right
panel). No CPT1C signal was detected from KO animals (WB:
anti-CPT1C; KO lanes). To demonstrate that the binding of
CPT1C to GluA1 is specific, as a negative control we used
neutral IgG to immunoprecipitate from WT homogenates. By
doing so, we proved that CPT1C is definitively pulled down
by GluA1 antibodies in different brain areas (Supplementary
1www.graphpad.com
FIGURE 1 | Carnitine palmitoyltransferase 1C (CPT1C) absence in knockout
(KO) animals translates into a lower AMPAR expression at neuronal surface.
(A) Coimmunoprecipitation of GluA1 and CPT1C from cortex, cerebellum and
hippocampal tissue of wild type (WT) and CPT1C KO showing GluA1-CPT1C
interaction in all tested brain areas. (B) Representative single confocal images
of immunofluorescence (IF) of 11 days in vitro (DIV) hippocampal pyramidal
neurons in culture from WT (upper images) and CPT1C KO (lower images)
animals. Surface GluA1 (Alexafluor 555; red signal) and intracellular GluA1
(Alexafluor 647; blue signal) is shown. (C) Examples of somatic currents
evoked by 20 µM AMPA +10 µM cyclothiazide during a 20 s fast application
pulse for WT (left trace) and CPT1C KO (right trace) hippocampal pyramidal
neurons. Two neurons with similar cell capacitance are shown. (D)
Quantification of endogenous somatic GluA1 surface to intracellular ratio from
pyramidal cells in culture. GluA1 ratio was diminished in neurons from CPT1C
KO animals compared with WT (∗∗∗p = 0.0003; Mann-Whitney-U-test).
Numbers in bars indicate the number of neurons analyzed. (E) CPT1C KO
pyramidal neurons display lower current density—measured at the steady
state current (∗∗p = 0.0035; Mann-Whitney-U-test). Numbers in bars denote
the number of recorded cells.
Figure S1). Thus, these experiments confirmed that CPT1C
interacts with GluA1 in all tested tissues and indicates that
CPT1C-mediated regulation of AMPARs might be a common
event throughout the CNS.
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AMPARs Surface Content Is Diminished in
CPT1C KO Mice
Since animals lacking CPT1C protein show reduced AMPAR-
mediated mEPSCs in hippocampal pyramidal cells (Fadó et al.,
2015), it is likely that somatic AMPAR content might be altered
as well in these neurons due to a lack of optimal trafficking. Thus,
we decided to study whether extrasynaptic somatic AMPAR
content was altered in CPT1C KO animals. First, we performed
IF experiments to determine the relative amount of AMPARs on
neuronal surface. We immunostained surface GluA1 in primary
hippocampal pyramidal neuronal cultures at 11 DIV (Figure 1B;
red signal) followed by permeabilization and staining of the
intracellular GluA1 pool (Figure 1B; blue signal). We calculated
the ratio of the surface expression of GluA1 subunit vs. the
intracellular level of GluA1 for every single cell. Figure 1D shows
the normalized ratio of surface to intracellular GluA1, where it
can be observed that this ratio was decreased in cultures from
CPT1C KO animals (100.00 ± 4.13% for WT vs. 75.34 ± 4.86%
for CPT1C KO; p = 0.0003; n = 29 analyzed cells for both
conditions from three different cultures). Since CPT1C is also
expressed in cortex where it coimmunoprecipitates with GluA1
(Figure 1A), we investigated whether the surface to intracellular
ratio of GluA1 could also be altered in cortical neurons in
culture. IF experiments were carried out with the same outcome
than in HPNs (100.00 ± 5.36% for WT cortical neurons vs.
73.41 ± 4.80% for CPT1C KO cortical neurons; p = 0.0006;
n = 25 analyzed cells for both conditions from three different
cultures; Supplementary Figure S2).
We next recorded whole-cell currents activated from
hippocampal pyramidal neurons in culture (14–15 DIV) by rapid
somatic application of 20 µM AMPA plus 10 µM cyclothiazide
to minimize AMPAR rapid desensitization. We found that
AMPAR-mediated currents were lower in CPT1C KO HPNs
compared to WT neurons (19.76 ± 2.51 pA/pF for WT vs.
10.36 ± 1.59 pA/pF for CPT1C KO; p = 0.0035; n = 16 cells
for both conditions from three and four different cultures,
respectively; Figures 1C,E). Thus, in addition to synaptic
AMPARs (Fadó et al., 2015), somatic content of AMPARs also
seems to be decreased in CPT1C deficient animals reinforcing
the positive role of CPT1C in AMPAR trafficking.
Identification of the Catalytic Triad in
CPT1C
Previous studies exploring CPT1C function have shown that
its canonical CPT1 catalytic activity is much lower than that
of CPT1A (Sierra et al., 2008). However, previous investigation
has pointed to a role for CPT1C in depalmitoylating AMPARs
although attempts to measure depalmitoylation using the Acyl
Biotin Exchange assay were not conclusive (Gratacòs-Batlle et al.,
2015). Thus, we decided to study this putative depalmitoylating
activity through other approaches in order to understand
the molecular mechanisms of CPT1C. For this purpose, an
in silico structural molecular model was constructed for human
CPT1C based on the crystal structure of human carnitine acetyl
transferase (Wu et al., 2003). The structural molecular model for
human CPT1C catalytic domain is shown in Figure 2A, where
His 470 is pointing towards the binding pocket. This histidine has
been shown to be crucial for CPT1A catalytic activity (Morillas
et al., 2001).
We then investigated a possible homology between the
structures of CPT1C and APT1, a crystallized depalmitoylating
enzyme (Devedjiev et al., 2000). Comparison of these two
molecular model structures allowed us to identify two residues
that together with His 470 could putatively endow thioesterase
activity in CPT1C. Specifically, residues Ser 252, His 470,
Asp 474 in CPT1C were located in positions corresponding
to residues Ser 114, His 203 and Asp 169 in the human
APT1 structure (Ser 119, His 208 and Asp 174 and in
human APT1 sequence; see Figures 2B,C). To validate Ser
252, His 470 and Asp 474 as the catalytic triad, we created
a CPT1C-GFP version in which those putative catalytic
residues were mutated to alanine, CPT1C(S252A, H470A,
D474A)—referred henceforth as CPT1C(CatTriad). In order to
explore whether this triple mutation could affect the interaction
between both proteins, a coimmunoprecipitation assay was
performed and subsequently analyzed by Western blotting
(n = 3). Figure 2D shows that GFP recognizing antibody could
pull down GluA1 when expressed together with CPT1C or
CPT1C(CatTriad). Additionally, GluA1-NT antibody could pull
down CPT1C and CPT1C(CatTriad) proteins revealing that
both proteins still interact regardless of the different mutations
introduced in CPT1C and suggesting also that the triplemutation
does not affect the native folding of the protein.
Following coimmunoprecipitation assays,
electrophysiological whole-cell recordings were performed
to assess whether the catalytic triad was important in
modulating AMPAR-induced currents. Figure 3A shows
typical currents mediated by GluA1 homomeric receptors
from –80 mV to +80 mV in the absence of CPT1C or together
with CPT1C or CPT1C(CatTriad). GluA1 currents were
increased in the presence of CPT1C as previously demonstrated
(78.00 ± 14.37 pA/pF for GluA1 alone vs. 143.7 ± 17.79 pA/pF
for GluA1+CPT1C; p = 0.0027; Mann–Whitney U-test;
n = 18 and 27, respectively; Figure 3B). Interestingly, there
was no statistical difference between current densities in cells
expressing GluA1 alone or together with CPT1C(CatTriad;
78.00 ± 14.37 pA/pF vs. 102.1 ± 17.12 pA/pF; p = 0.2144;
Mann–Whitney U-test; n = 18 and 26, respectively; Figure 3B)
and current density values for CPT1C(CatTriad) were lower
than in CPT1C co-expression (p = 0.0134; n = 27 and 26 for
GluA1+CPT1C and GluA1+CPT1C(CatTriad) respectively).
The increase in CPT1C-dependent GluA1-mediated currents has
been correlated with an increase in the surface to intracellular
ratio of GluA1 subunit (Gratacòs-Batlle et al., 2015). Therefore,
we performed IF experiments of GluA1 in the absence or
presence of WT or the mutated form of CPT1C (Figure 3C).
WT CPT1C increased surface/intracellular GluA1 ratio
as previously shown (100.0 ± 5.17% for GluA1alone vs.
123.1 ± 5.43% GluA1+CPT1C; p = 0.0048; Mann–Whitney
U-test; n = 103 and 94 respectively from three different IF;
Figure 3D). The analysis of IF experiments showed that the
increase in GluA1 ratio content at the cell surface observed
with CPT1C was lost in CPT1C(CatTriad; 123.1 ± 5.43% for
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FIGURE 2 | Identification of a putative catalytic triad in CPT1C. (A) Molecular model of human CPT1C based on the determined structure of human carnitine
acetyltransferase. Residue His 473, conserved among CPTs (His 470 in CPT1C), is displayed in sticks. (B) Structure of acyl protein thioesterase 1 (APT1; PDB ID
1FJ2). Ser 114, His 203 and Asp 169 from the catalytic triad are displayed in sticks. (C) CPT1C molecular model. Ser 252, His 470 and Asp 474 putative catalytic
residues are displayed in sticks. The putative catalytic residues in CPT1C were identified based on the relative disposition of the catalytic residues in the structure of
APT1. (D) Coimmunoprecipitation showing that mutated CPT1C(S252A, H470A, D474A)-GFP—CPT1C(CatTriad)—does not affect the interaction with GluA1.
Anti-GFP antibodies pull-down GluA1 when expressed together with CPT1C(CatTriad), (middle lanes, upper panel). GluA1 recognizing antibodies pull down
CPT1C(CatTriad), (right lanes, lower panel). This experiment was replicated three times.
GluA1+CPT1C vs. 97.15 ± 3.89% GluA1+CPT1C(CatTriad);
p = 0.0005; Mann–Whitney U-test; n = 94 and 108 respectively
from three differerent IF; Figure 3D). Indeed, the ratio
of GluA1+CPT1C(CatTriad) was not different from
GluA1 alone (100.0 ± 5.17% for GluA1 vs. 97.15 ± 3.89%
GluA1+CPT1C(CatTriad); p = 0.7496; Mann–Whitney U-test;
n = 103 and 108 respectively from three different IF; Figure 3D).
Based on these results we propose that Ser 252, His 470 and
Asp 474 constitute the catalytic triad in CPT1C, suggesting that
CPT1C has a depalmitoylating activity that is responsible for its
effect on GluA1.
CPT1C H470 Is Crucial in the Enhancement
of AMPAR Surface Expression
Given that the mutation of the catalytic triad abolishes the
CPT1C effect on GluA1, we next decided to focus on one
of these residues to test whether it was crucial for its
activity. Given the importance of His 473 in CPT1s activity
(Morillas et al., 2001), we used site-directed mutagenesis to
create a mutant version of CPT1C where this important
histidine was changed to alanine (H470A in CPT1C) to allow
us to check if this residue alone is crucial for the CPT1C
effect on GluA1. As previously done for CPT1C(CatTriad),
we performed coimmunoprecipitation assays to evaluate the
correct interaction between GluA1 and CPT1C(H470A). As
expected from the results obtained in Figures 2D, 4A shows
that both proteins still interact regardless of the mutation
introduced to CPT1C. We then did electrophysiological and IF
experiments to test the ability of CPT1C(H470A) to modulate
GluA1 currents. Patch-clamp recordings such as the ones
presented in Figure 4B showed an increase in AMPARwhole-cell
current densities at –80 mV with CPT1C (82.39 ± 15.83 pA/pF
for GluA1 alone vs. 149.7 ± 19.98 pA/pF GluA1+CPT1C;
p = 0.0051; Mann–Whitney U-test; n = 25 and 19, respectively;
Figures 4B,D). As hypothesized, CPT1C(H470A) did not
increase GluA1 mediated currents (82.39 ± 15.83 pA/pF for
GluA1 vs. 78.98 ± 18.26 pA/pF for GluA1+CPT1C(H470A);
p = 0.6209; Mann–Whitney U-test; n = 25 and 20, respectively;
Figure 4D), indicating that the His 470 residue plays a
crucial role in GluA1 subunit modulation. In the same
line, IF analysis (Figure 4C) showed that the increase
in GluA1 surface/intracellular ratio observed with CPT1C
(100.0 ± 5.3% for GluA1 vs. 123.5 ± 5.25% for GluA1+CPT1C;
p = 0.0033; Mann–Whitney U-test; n = 104 and 94, respectively
from three independent IF; Figure 4E) was not present
with CPT1C(H470A; 123.5 ± 5.25% for GluA1+CPT1C vs.
102.2 ± 4.04% for GluA1+CPT1C(H470A); p = 0.0022;
Mann–Whitney U-test; n = 104 and 147, respectively from three
independent IF; Figure 4E) indicating that His 470 is crucial for
CPT1C-mediated GluA1 surface trafficking enhancement.
Molecular Model of CPT1C Complexed to
Carnitine, CoA and Palmitate
Once the importance of the triad—andHis 470—in CPT1C effect
onGluA1 had been assessed, we further tested the hypothesis that
CPT1C is a depalmitoylating enzyme of AMPARs. Figure 5A
shows the structural molecular model of human CPT1C
complexed to carnitine, CoA and palmitate, where Ser 252,
His 470 and Asp 474 point towards carnitine and palmitate
molecules, reinforcing the hypothesis that CPT1C could perform
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FIGURE 3 | CPT1C possesses a functional catalytic triad. (A) Examples of whole-cell currents between –80 mV and +80 mV evoked by 1 mM glutamate plus 25 µM
cyclothiazide in tsA201 transfected cells with GluA1 alone (GluA1+GFP), together with CPT1C or CPT1C(CatTriad). Cells with similar cell capacitance are shown.
(B) Average of current density (–pA/pF) at –80 mV for GluA1 alone and together with CPT1C or CPT1C(CatTriad). CPT1C increased GluA1-mediated currents
(∗∗p < 0.01; Mann-Whitney-U-test) while mutation of Ser 252, His 470 and Asp 474 to alanine in CPT1C avoided the enhancement of the currents (#p < 0.05;
Mann-Whitney-U-test). Numbers in bars denote the number of recordings. (C) Representative confocal images of tsA201 cells co-transfected with GluA1+GFP (left
panel), GluA1+CPT1C (middle panel) or GluA1+CPT1C(CatTriad), (right panel) where surface GluA1 was labeled with anti-GluA1-NT and Alexafluor 555 (red signal)
and intracellular GluA1 was labeled with same anti-GluA1-NT primary antibody plus Alexafluor 647 (blue signal). Scale bars: 50 µm. (D) Quantification of the
GluA1 surface to intracellular ratio normalized to GluA1 and expressed as a percentage. The increment in surface expression due to CPT1C (∗∗p < 0.01;
Mann-Whitney-U-test) was abolished when Ser 252, His 470 and Asp 474 were changed to alanine in CPT1C (###p < 0.001; Mann-Whitney-U-test). Numbers in
bars denote the number of quantified cells from three different IF experiments.
a putative thioesterase activity. In addition, the molecular model
shows that CoA and carnitine are highly accessible in the CPT1C
structure (see Figures 5B,C respectively), suggesting that CPT1C
would be able to bind a region of GluA1 instead of CoA.
CPT1C Effect on AMPARs Is Abolished by
Treatment With the Protein Thioesterase
Inhibitor Palmostatin B
Since PB is a potent inhibitor of APT1 activity (Dekker
et al., 2010), and considering the high structural homology
between the APT1 and CPT1C catalytic triads, we decided
to use this compound as a tool to investigate the role of
palmitoylation in AMPAR modulation by CPT1C protein.
We first did a coimmunoprecipitation assay to check if this
compound could affect the AMPAR-CPT1C interaction. Cells
were transiently transfected with GluA1 and CPT1C-GFP
and 24 h later were treated during a time period of 24 h
with either 50 µM PB or 0.1% DMSO (vehicle used to
resuspend a 50 mM stock solution of PB). Afterwards, the
compound was removed and the membranes of the transfected
cells were immunoprecipitated with anti-GFP or with anti-
GluA1. Figure 5D shows that treatment with PB does not
alter GluA1 and CPT1C interaction. After confirming the
interaction of GluA1 and CPT1C with Co-IP experiments,
electrophysiological recordings were performed to evaluate
the possible effect of PB on GluA1 mediated currents when
co-expressed with CPT1C (Figure 5E). As control, in non
PB treated cells, CPT1C increased GluA1 current density
(105.1 ± 16.94 pA/pF for GluA1 vs. 193.2 ± 14.58 pA/pF
for GluA1+CPT1C; p = 0.0011; Mann–Whitney U-test;
n = 20 and 16 respectively). No statistical difference was found
in GluA1 current density when expressed alone compared with
the same condition but treated with PB (105.1 ± 16.94pA/pF
vs. 147.4 ± 22.28 pA/pF; p = 0.1666; Mann–Whitney U-test;
n = 20 and 15 respectively). Interestingly, PB treatment abolished
the increase in current density due to CPT1C co-expression
(193.2± 14.58 pA/pF for non-treated GluA1+CPT1C transfected
cells vs. 107.4± 14.36 pA/pF for PB treated GluA1+CPT1C cells;
p = 0.0007; Mann–Whitney U-test; n = 16 and 22 respectively).
This experiment indicates that PB suppresses the GluA1-
enhancing properties of CPT1C most probably by inhibiting its
PTE activity.
H470A Mutation Impairs CPT1C Activity in
Hippocampal Neurons
We next decided to explore the role played by histidine 470 of
CPT1C in neurons. Thus, we prepared primary neuronal cultures
from CPT1C KO mice in which we overexpressed either WT
CPT1C or CPT1C(H470A) and studied both GluA1 levels by IF
and AMPAR-mediated currents with electrophysiology.
Figures 6A,B shows how CPT1C expression in KO neurons
rescued GluA1 somatic levels compared with GFP expressing
neurons measured by IF (100.00 ± 5.36% vs. 124.9 ± 7.67%
for GFP and CPT1C respectively; p = 0.0132, Mann-Whitney
U-test; n = 32 and 30 neurons). The increase in GluA1 surface
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FIGURE 4 | Histidine 470 is crucial in CPT1C-mediated AMPAR effect.
(A) Western blot showing that mutated CPT1C(H470A) interacts with GluA1.
Anti-GFP antibodies could pull-down GluA1 when expressed together with
CPT1C or CPT1C(H470A), (middle lanes, upper panel). GluA1 recognizing
antibodies pull down both CPT1C and CPT1C(H470A), (right lanes, lower
panel). This experiment was replicated three times. (B) Whole-cell
GluA1-mediated currents between –80 mV and +80 mV in three example cells
with similar membrane capacitance transfected with GluA1 alone
(GluA1+GFP; left trace), together with CPT1C (middle trace) or
CPT1C(H470A), (right trace). (C) Representative confocal images of
tsA201 cells co-transfected with GluA1+GFP (left panel), GluA1+CPT1C
(middle panel) or GluA1+CPT1C(H470A), (right panel). Surface and
intracellular GluA1 were labeled with anti-GluA1-NT and Alexaflour 555 (red
signal) or Alexaflour 647 (blue signal) as described in “Materials and Methods”
section. Scale bars: 50 µm. (D) Average of normalized currents at –80 mV for
the three conditions shown in (B). CPT1C increased GluA1-mediated currents
(∗∗p < 0.01; Mann-Whitney-U-test) while removal of catalytic His 470 in
CPT1C avoided the enhancement of the currents (#p < 0.05;
Mann-Whitney-U-test). Numbers in bars denote the number of recordings.
(E) Quantification of the GluA1 surface to intracellular ratio normalized to
GluA1 and expressed as a percentage. The increment in surface expression
due to CPT1C (∗∗p < 0.01; Mann-Whitney-U-test) was abolished when
catalytic His 470 was neutralized (###p < 0.001; Mann-Whitney-U-test).
Numbers in bars denote the number of analyzed cells from three different IF
experiments.
expression was not significantly different from GFP expressing
neurons when the mutated CPT1C(H470A) was used instead
of WT CPT1C (100.00 ± 5.36% vs. 106.5 ± 8.55% for GFP
and CPT1C(H470A) respectively; p = 0.8551, test; n = 32 and
26 neurons).
These results point to a role for histidine 470 in CPT1C
in mediating the increase in AMPARs to the cell surface.
However, in order to functionally assess the impact of the
mutation, we recorded whole-cell somatic AMPAR currents.
We rapidly applied AMPA plus cyclothiazide to the soma
of hippocampal pyramidal neurons and recorded the evoked
currents (Figure 6C). CPT1C enhanced the AMPAR-mediated
responses (20.86 ± 4.93 pA/pF vs. 44.28 ± 6.64 pA/pF for
GFP and CPT1C respectively; p = 0.0101 Mann-Whitney U-test;
n = 15 and 9) in contrast to CPT1C(H470A) where no difference
from the control cells was observed, confirming the requirement
of the CPT1C catalytic histidine for the increase of the currents
(20.86 ± 4.93 pA/pF vs. 18.77 ± 4.15 pA/pF for GFP and
CPT1C(H470) respectively; p = 0.9641 Mann-Whitney U-test;
n = 15 and 12) as shown in Figure 6D.
CPT1C Possess Protein Thioesterase
Activity Which Is Dependent on Residue
H470
So far, the results obtained with CPT1C(H470A) seem to
indicate that this protein exerts its effects on GluA1-containing
AMPARs by a depalmitoylating mechanism. Consistent with
this, CPT1C enhancement of surface AMPARs depends on the
palmitoylable residue of GluA1, C585 (Gratacòs-Batlle et al.,
2015). However, in the past, the putative depalmitoylating
activity of CPT1C was assessed by means of an ABE assay
without clear conclusions (Gratacòs-Batlle et al., 2015). We
addressed the CPT1C depalmitoylating activity by means of
an ABE assay in a HEK293-AD line constitutively expressing
GluA1 (HEK293-GluA1) and overexpressing the palmitoyl
acetyl transferase—DHHC3/GODZ—that palmitoylates the
C585 residue of GluA1 (Hayashi et al., 2005). We reasoned that
if basal GluA1 palmitoylation levels on C585 were higher the
putative depalmitoylation effect of CPT1C would be more easily
observed.
Hence, we transfected HEK293-GluA1 cells with either
GODZ+GFP or GODZ+CPT1C and we performed the ABE
assay (Figure 7A). As hypothesized, we observed a decrease
in palmitoylation levels of GluA1 subunit when CPT1C was
present (100% for GODZ+GFP vs. 75.59 ± 13.04% for
GODZ+CPT1C; p = 0.0079; Mann-Whitney U-test; n = 5;
Figure 7B). This directly demonstrates that CPT1C is able to
decrease GluA1 palmitoylation. Importantly, cells expressing the
mutant H470A form of CPT1C had GluA1 palmitoylation levels
similar to those of GFP transfected cells indicating that GluA1-
dependent depalmitoylation by CPT1C relies on its catalytic
residue histidine 470 (100% for GODZ+GFP vs. 100.70 ± 0.78%
for GODZ+CPT1C(H470A); p = 0.4643; Mann-Whitney U-test;
n = 5 and 3, respectively; Figure 7B). These experiments
demonstrate that CPT1C is able to remove palmitate groups from
GluA1 and that this catalytic activity depends on histidine 470.
CPT1C Effect on GluA1 Is Isoform Specific
and Restricted to Endoplasmic Reticulum
It has been shown in the past that CPT1A does not share
the ability of CPT1C to modulate AMPAR surface expression
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FIGURE 5 | CPT1C displays depalmitoylation features. (A) Molecular model of CPT1C complexed to carnitine, CoA and palmitate. Ser 252, His 470 and Asp
474 are pointing toward the binding pocket and are proposed to be the catalytic residues in CPT1C depalmitoylating activity. (B) CoA (in orange) is observed in
CPT1C molecular model, suggesting that the substrate (small region of GluA1) could access to the binding pocket through this cavity. (C) A cavity next to carnitine
(in blue) is also observed, suggesting that palmitoylcarnitine can exit the binding pocket through this cavity. (D) Coimmunoprecipitation showing that Palmostatin B
(PB)—an inhibitor of palmitoyl thioesterase (PTE) activity—treatment does not affect the interaction of CPT1C with GluA1. (E) Average of normalized current density
at −80 mV for GluA1 alone (+GFP) or together with CPT1C with and without treatment with PB. CPT1C increased GluA1 current density in the absence of PB
(∗∗p < 0.01; Mann-Whitney-U-test). Current density was decreased to control levels (GluA1 alone) when cells co-expressed GluA1 and CPT1C but treated with PB
(###p < 0.001; Mann-Whitney-U-test). There was no statistical difference in GluA1 current density when expressed alone, with or without PB treatment (nsp > 0.05;
Mann-Whitney-U-test). Numbers in bars represent the number of recorded cells.
(Gratacòs-Batlle et al., 2015).We next decided to explore whether
the effect of CPT1C on AMPARs is due to its specific ER
localization and whether CPT1A could exert a similar effect
on AMPAR mediated currents when targeted to ER. For this
purpose we took advantage of the fact that the N-terminus of
CPT1s is responsible for targeting CPT1C and CPT1A to specific
intracellular locations (Sierra et al., 2008). Concretely, while
the CPT1C N-terminal domain determines its ER targeting,
the N-terminal domain of CPT1A contains a mitochondrial
import signal (Cohen et al., 2001), which is responsible for
its mitochondrial location (Figure 8A; left). Two chimeric
proteins were used, where the N-terminal region of CPT1C
was cloned into the CPT1A-GFP plasmid (named hereafter:
C-CPT1A) and the N-terminal region of CPT1A replaced
the equivalent region in the CPT1C-GFP plasmid (named
hereafter: A-CPT1C), thus switching their intracellular locations
(Figure 8A; right).
First, to confirm CPT1A and CPT1C mislocalization, these
constructs were transfected in COS-7 cells. Co-localization
imaging experiments were performed with these constructs
and MitoTracker (a potential-sensitive dye that accumulates
in mitochondria) or KDEL-DsRed (ER marker). As can be
observed in the confocal photo-micrographs in Figure 8B,
CPT1A with the localization motif of CPT1C (C-CPT1A) shows
a clear ER pattern (six upper panels), meanwhile CPT1C with
the localization domain of CPT1A (A-CPT1C) localizes at
the mitochondria (six lower panels). Quantification of these
localizations was performed by using MOC as shown in
Figure 8C. Hence, we confirmed that the subcellular locations of
CPT1C and CPT1A could be changed by switching their location
Frontiers in Molecular Neuroscience | www.frontiersin.org 11 August 2018 | Volume 11 | Article 275
Gratacòs-Batlle et al. AMPAR Modulation by CPT1C
FIGURE 6 | CPT1C but not CPT1C(H470A) increases functional AMPAR surface expression in CPT1C KO pyramidal neurons. (A) Representative confocal IF images
of 11 DIV hippocampal pyramidal neurons in culture from CPT1C KO mice transfected with GFP (left images), CPT1C (middle images) or CPT1C(H470A), (right
images). Upper panels display the analyzed transfected neuron. Surface GluA1 (Alexafluor 555; red signal) and intracellular GluA1 (Alexafluor 647; blue signal) is
shown in the lower panels for the three different conditions. Scale bars: 10 µm. (B) Quantification of endogenous somatic GluA1 surface to intracellular ratio from
CPT1C KO pyramidal cells in culture. GluA1 ratio was increased in neurons transfected with CPT1C compared with GFP (∗p = 0.0132; Mann-Whitney U-test) while
CPT1C(H470A) was not able to significantly increase GluA1 ratio (nsp = 0.8551; Mann-Whitney U-test). Numbers in bars indicate the number of neurons analyzed.
(C) Endogenous AMPAR somatic currents evoked by rapid application of 20 µM AMPA +10 µM cyclothiazide during 20 s from CPT1C KO hippocampal pyramidal
neurons transfected with GFP (left trace), CPT1C (middle trace) or CPT1C(H470A), (right trace). Three neurons with similar cell capacitance are shown. (D)
Quantification of peak responses (shown as current density) from CPT1C KO pyramidal neurons in the conditions mentioned in (C). Currents were clearly increased
in neurons expressing CPT1C but not in cells expressing CPT1C(H470A). Numbers inside bars denote the number of recorded cells.
motifs. Next, in order to assess the functional consequences of
CPT1A and CPT1C on GluA1 when they are in a different
subcellular location from their usual one, electrophysiological
whole-cell recordings were carried out using tsA201 cells
FIGURE 7 | CPT1C acts as depalmitoylating enzyme of GluA1. (A) Palmitoylation levels detected with Acyl-Biotin Exchange (ABE) assay of GluA1 alone (GFP), or
together with CPT1C-GFP or CPT1C(H470A) in HEK293AD-GluA1 expressing cells transfected with DHHC3/GODZ palmitoylating enzyme. The biotinylated
GluA1 immunoprecipitates subsequent to the ABE assay for all conditions were subjected to SDS-PAGE. Palmitoylation of GluA1 subunit is detected only in
plus-hydroxylamine (+HAM) samples (three lanes from the left). −HAM samples control non-specific incorporation of biotin (three lanes from the right).
GluA1 palmitoylation levels (right top) were detected by Western blotting with streptavidin-HRP (palmitoylation). The total amount of immunoprecipitated GluA1 was
detected by Western blotting with anti-GluA1-NT antibody (anti-GluA1, bottom) after stripping the membranes. (B) Quantification of palmitoylation levels for
GluA1 alone (GFP), together with CPT1C or CPT1C(H470A) in HEK293AD cells constitutively expressing GluA1. Ratio of palmitoylated GluA1 to total GluA1
is shown as mean and S.E.M. (∗∗p < 0.01 and nsp > 0.05; Mann-Whitney U test; n = 5, 3 and 3, respectively).
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FIGURE 8 | CPT1C effect on AMPAR currents is isoform specific and
depends on ER location. (A) N-terminal domain of CPT1s determines its
intracellular location. Chimeric proteins C-CPT1A (CPT1A with the location
domain of CPT1C) and A-CPT1C (CPT1C with the location domain of CPT1A)
are miss-localized to endoplasmic reticulum (ER) and mitochondria (MIT/MT),
respectively. (B) Confocal images showing CPT1s-GFP signal in green (left
columns), KDEL or mitotracker signal in red (middle column) and merged
images (right columns) for the two chimeric CPT1s proteins. C-CPT1A clearly
co-localizes with ER while A-CPT1C is not co-localizing with KDEL ER marker.
(C) Representation of co-localization values quantified by Manders’ overlap
Coefficient (MOC) expressed as mean ± SEM. Numbers in bars denote
number of analyzed cells (∗p < 0.05; ∗∗, ##p < 0.01; Mann-Whitney-U-test).
(D) Average of normalized current density at –80 mV for GluA1 alone or
together with CPT1C or chimeric proteins. No significant differences were
found between GluA1 current density (–pA/pF) in cells co-expressing
A-CPT1C or C-CPT1A (nsp > 0.05; Mann-Whitney-U-test).
expressing GluA1 alone, in presence of CPT1C or with chimeric
C-CPT1A and A-CPT1C. As seen before, Figure 8D shows that
GluA1 current density was lower in cells expressing GluA1 alone
when compared with cells expressing GluA1 together with
CPT1C (80.83 ± 11.75 pA/pF vs. 133.9 ± 16.29 pA/pF;
p = 0.0062; Mann–Whitney U-test; n = 23 and 31, respectively).
GluA1 current density in cells expressing GluA1 alone
was similar to the current density of cells co-expressing
miss-localized CPT1C (A-CPT1C; 80.83 ± 11.75 pA/pF vs.
102.7 ± 16.29 pA/pF; p = 0.1571; Mann–Whitney U-test;
n = 23 and 16, respectively) indicating that the effect of CPT1C
depends on its ER location. Interestingly, no differences were
found when comparing cells expressing GluA1 alone or with
GluA1 co-expressed with CPT1A at ER location (C-CPT1A;
80.83 ± 11.75 pA/pF vs. 97.24 ± 16.97 pA/pF; p = 0.1571;
Mann–Whitney U-test; n = 23 and 14, respectively) indicating
the inability of CPT1A to act on AMPARs.
Palmitoylation of AMPARs occurs at the Golgi Apparatus
(GA) by DHHC3/GODZ on Cysteine 585 (Hayashi et al.,
2005). To date no DHHCs capable of palmitoylating GluA
subunits have been described to be present at the ER and hence
palmitoylate AMPARs at early stages. This raises the question
of how CPT1C—an ER resident protein—can depalmitoylate
a protein that is normally being palmitoylated at the GA.
One possibility is that both processes occur sequentially in
the transition between ER and GA, which is performed via
COPII vesicles (Watson and Stephens, 2005). In fact, anterograde
transport of GluA1 from ER to Golgi, which is mediated by
COPII vesicles, is important for GluA1 palmitoylation in neurons
(Yang et al., 2009). Thus, we next wanted to investigate whether
CPT1C was present in these vesicles apart from the ER, which
would allow depalmitoylation of GluA1 at COPII vesicles. To
test that hypothesis, we performed co-localization experiments
of CPT1C-GFP with Sec31A (COPII marker). MOC showed
values of 0.62 ± 0.03 (n = 15; Supplementary Figure S3), which
were not conclusive. Thus, to determine if this MOC value
was indicating the presence of CPT1C in COPII vesicles, we
performed co-localization experiments between Sec31A (COPII
marker) and Sec61B-GFP (ER marker; Johnson and van Waes,
1999). We obtained a MOC value of 0.61 ± 0.003 (n = 9;
Supplementary Figure S2), which was not significantly different
from the MOC value between CPT1C and Sec31A (p = 0.7622)
suggesting that this value is due to the close proximity of the ER
to COPII vesicles and not due to the specific presence of CPT1C
in COPII.
In summary, this data indicates that the depalmitoylating
effect of CPT1C on AMPARs is clearly CPT1C specific and
possibly happens at ER level.
DISCUSSION
For many years, it has been known that AMPARs are key
elements in synaptic function. However, during the last decade,
the AMPAR field has been transfigured by the gradual discovery
of transmembrane proteins interacting with AMPARs that
regulate and determine their function in the brain. In 2012,
proteomic studies (Schwenk et al., 2012; Shanks et al., 2012)
defined several new proteins that were able to interact with
AMPAR subunits. We previously described a novel role for
one of these proteins (CPT1C) in GluA1-containing AMPAR
function (Gratacòs-Batlle et al., 2015) whereby CPT1C increases
the surface expression of this ionotropic glutamate receptor
subtype. Since prior results indicate that CPT1C fails to promote
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GluA2 homomeric AMPAR trafficking (Gratacòs-Batlle et al.,
2015), in this work we have focused on GluA1 subunit of
AMPARs due to the apparent subunit specificity of CPT1C
effect. However, future experiments might try to resolve whether
other AMPAR subunits (GluA3 and GluA4) can be targeted by
CPT1C and which could be the determinants of the differences
found between GluA1 and GluA2. Our results reinforce the
evidence of CPT1C importance in AMPAR regulation by
showing that GluA1 clearly coimmunoprecipitates with CPT1C
in brain extracts from cortex, cerebellum or hippocampus and
modulates somatic AMPAR content in pyramidal neurons. The
interaction presented here confirms previous reports of GluA1-
CPT1C interaction from mouse/rat whole brain extracts in
proteomic studies (Schwenk et al., 2012, 2014) and from mouse
hippocampal neuronal cultures (Fadó et al., 2015). Interestingly,
our coimmunoprecipitation data from brain extracts in Figure 1
show lower amounts of GluA1 protein in all tested brain areas
in CPT1C KO animals compared with WT animals. In this
regard, previous studies have attributed a role for CPT1C in
stabilizing and controlling GluA1 synthesis in cultured HPNs
(Fadó et al., 2015). Our results reinforce this hypothesis and
suggest a similar decrease in expression for GluA1 in cerebellar
and cortical neurons of CPT1C deficient animals (Figure 1A,
left panel). CPT1C function in the central nervous system (CNS)
has been demonstrated to be important in hypothalamic control
of food intake (Wolfgang et al., 2006) and in hippocampal
function as can be inferred from the learning deficits in CPT1C
KO animals (Carrasco et al., 2012). Specifically, CPT1C-lacking
mice display poor performance in the Morris water maze
(Carrasco et al., 2012)—a task that clearly explores hippocampal
function but also depends on cortical areas (D’Hooge and De
Deyn, 2001). Moreover, CPT1C deficient mice have motor
coordination impairment (Carrasco et al., 2013), which is
indicative of cerebellar malfunctioning. Our data showing a
widespread GluA1-CPT1C interaction in the CNS and a deficit
of somatic AMPARs in hippocampal and cortical neurons
from CPT1C KO animals reinforces the idea that CPT1C
plays an important role in modulating AMPARs in these brain
regions.
However, the main scope of this work has been focused on
resolving the molecular mechanisms of CPT1C modulation
of AMPARs. Given that CPT1C binds palmitoyl-CoA and
is able to form palmitoylcarnitine (Sierra et al., 2008), we
considered whether CPT1C could depalmitoylate GluA1, which
would explain the increase in AMPAR surface expression.
Palmitoylation/depalmitoylation of C585 and C811 in
GluA1 determine trafficking properties and surface stability
of AMPARs (Hayashi et al., 2005; Yang et al., 2009; Lin
et al., 2009). Indeed, the palmitoylable cysteine 585 of the
GluA1 subunit has been proved to be crucial for the CPT1C
enhancement of AMPAR trafficking although no changes
in the palmitoylation state of GluA1 could be observed
(Gratacòs-Batlle et al., 2015). In order to gain insight into the
functional role of CPT1C, we constructed a structural model of
human CPT1C as a tool to elucidate the molecular mechanism
of a putative depalmitoylating activity. The structural similarity
of the CPT1C molecular model and protein thioesterases
permitted the identification of Ser 252, His 470 and Asp 474 as
the catalytic triad responsible for depalmitoylating activity
in CPT1C. We have also constructed a structural molecular
model of CPT1C complexed to carnitine, CoA and palmitate,
where the side-chains of the residues from the catalytic triad
point towards these molecules (see Figure 5A). Based on this
structural model, the palmitoylated substrate (a small region
of GluA1) would access the binding pocket through the CoA
cavity (Figure 5B) exposing the palmitate moiety to the catalytic
triad.
AMPARs at ER are positioned in such a way that their
palmitoylation sites are facing the cytoplasmic side (Gan et al.,
2015). The catalytic domains of CPT1A and B face the cytoplasm
(Fraser et al., 1997) and this is also the case for CPT1C
(Supplementary Figure S4). This topology of CPT1C at the
ER would allow contact between the CPT1C catalytic domain
and the palmitoylable cysteine residues of the AMPARs. The
residues from the catalytic triad of CPT1C domain would
perform the thioesterase activity, thus transferring the palmitoyl
moiety from the substrate (GluA1) to the carnitine molecule.
The resulting palmitoylcarnitine molecule would be able to
exit through another cavity opposite to the GluA1 binding
pocket (corresponding to the carnitine cavity, Figure 5C).
Experiments performed with two catalytic mutant versions of
CPT1C—CPT1C(H470A) and CPT1C(CatTriad)—validate our
model. First, in these CPT1C versions, the increase in AMPAR
surface expression mediated by CPT1C was abolished indicating
that the effect of CPT1C on GluA1 subunits was most probably
mediated by the depalmitoylating activity of CPT1C. Second,
PB, a compound known to specifically inhibit APT1 thioesterase
activity (Dekker et al., 2010), was able to preclude the increment
in AMPAR-mediated responses, strongly suggesting that CPT1C
acts as a depalmitoylating enzyme, and third, this work directly
demonstrates the depalmitoylating activity of CPT1C, which
probably accounts for the effect on AMPAR traffic enhancement.
Previous results hinted at the possible depalmitoylating role
of CPT1C since its effect on AMPARs was abolished in the
non-palmitoylable version of GluA1 subunit, GluA1(C585S;
Gratacòs-Batlle et al., 2015). However, this previous work failed
to demonstrate a depalmitoylating activity of CPT1C. Similarly,
other works did not found a putative CPT1 catalytic activity
for CPT1C equivalent to CPT1A and CPT1B (Sierra et al.,
2008). Here we have tried to improve the ABE assay sensitivity
by decreasing the variability in basal palmitoylation levels of
GluA1 subunits, which might account for the variability found
in earlier work (Gratacòs-Batlle et al., 2015). We have used
DHHC3/GODZ—a specific palmitoyl acetyl transferase that
palmitoylates GluA1 at cysteine residue 585 (Hayashi et al.,
2005)—to increase the palmitoylation levels of GluA1 in order
to reliably detect depalmitoylating activity of CPT1C. Under
these conditions, we were able to observe differences in the
palmitoylation levels of GluA1. The fact that CPT1C(H470A)
did not alter the palmitoylation levels of GluA1 compared
with control conditions supports the depalmitoylating activity
of CPT1C and points towards the importance of this catalytic
histidine in the depalmitoylation process. This is not surprising
since mutations affecting the catalytic histidine of LYPLA1, a
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thioesterase that depalmitoylates the BKCa channels, impair
the depalmitoylation activity of this enzyme (Tian et al.,
2012).
The rescue experiments performed in this work reinforce the
importance of CPT1C—and its catalytic activity—in neuronal
physiology. In CPT1C deficient hippocampal pyramidal neurons,
the re-expression of CPT1C increased the surface/intracellular
ratio of GluA1 while CPT1C(H470A) did not. Furthermore,
CPT1C(H470) failed to upregulate AMPAR-mediated currents
in this same neuronal type when CPT1C clearly increased the
somatic currents.
Thus, collectively our experiments prove the involvement
of a depalmitoylation process in the CPT1C-mediated increase
of surface AMPARs and also show that CPT1C acts on
AMPAR through an enzymatic activity (dependent on a catalytic
histidine) and not due to a mere structural interaction. This
function of CPT1C is maintained in neurons since neutralization
of the catalytic residue H470 abolishes the ability of CPT1C to
exert its effect on native AMPARs from hippocampal pyramidal
cells.
Previous studies have shown that GluA1 modulation is
specific to the CPT1C isoform. The possibility that CPT1A could
mediate the same effect as CPT1C on AMPAR function was
previously explored (Gratacòs-Batlle et al., 2015) due to the
high degree of homology between both isoforms (Price et al.,
2002) and concluded that CPT1A was incapable of modulating
AMPAR trafficking. Nevertheless, the subcellular locations of
CPT1A and GluA1 are totally different and perhaps this is the
basis for the lack of effect of CPT1A on GluA1 trafficking.
Here we have circumvented that issue by targeting CPT1A to
the ER, where it can be in direct contact with GluA1. Our
results show that when CPT1A localizes at the ER together
with GluA1 it does not modulate AMPAR-induced currents
as CPT1C does, confirming the specificity of this member of
the CPT1 family and supporting the hypothesis of a different
enzymatic activity for CPT1C. On the other hand, the ER
location of CPT1C seems to be an essential requirement for
modulating AMPAR surface expression as mislocalization of
CPT1C abolishes its effect on AMPAR currents. Co-localization
studies have shown that GluA1-CPT1C interaction only occurs
at ER level and not at other cell locations as GA or cell
surface (Gratacòs-Batlle et al., 2015). Moreover, it has been
recently shown that CPT1C binds exclusively to a pool of
AMPARs that are devoid of auxiliary subunits as CNIHs
or TARPs. This population of AMPARs is only found at
the ER and not at other cell locations as GA or plasma
membrane (Brechet et al., 2017), reinforcing the idea presented
here that the CPT1C mediates its effects exclusively at the
ER. This conclusion implies that a palmitoyl acyl transferase
(putatively a member of DHHC family) should be present at
ER, and to date no DHHC proteins capable of palmitoylating
GluA1 have been found at ER. Another possibility is that
palmitoylated AMPARs undergo retrograde traffic form the
GA to the ER via COPI vesicles (Spang, 2013; Fleck, 2006).
Indeed, palmitoylation by DHHC3 of GluA2 subunits on
residue C610 at TM2 (the equivalent residue to C585 in
GluA1) accumulates AMPARs at the GA (Hayashi et al., 2005),
which might favor their retrograde transport to the ER and
thus make them a target for CPT1C depalmitoylation. The
significance of palmitoylation at the GA and such putative
AMPAR retrograde traffic is unknown, but it may form part
of AMPAR quality control mechanisms (Penn et al., 2008;
Coleman et al., 2010). Future investigation might resolve this
caveat.
Together with CPT1C, a series of proteins forming part of
the peripheral core of AMPAR complex have been described
recently to affect AMPAR trafficking: porcupine protein has
been shown to control AMPAR levels at the synapse (Erlenhardt
et al., 2016); FRRS1L and CPT1C cooperatively act to favor
AMPAR traffic to plasma membrane by priming the complex
for TARPs and CNIHs association (Brechet et al., 2017);
α/β-hydrolase domain-containing 6 (ABHD6) has a negative
role on AMPAR trafficking (Wei et al., 2016). All these
proteins are not present in TARPed AMPARs at the cell
surface (Brechet et al., 2017), and their role seem to be
restricted to intracellular compartments. Our work confirms
these previous findings of CPT1C’s role on AMPARs trafficking
(Gratacòs-Batlle et al., 2015; Brechet et al., 2017) and sheds
light on the mechanism of the positive trafficking effect on
AMPARs by suggesting that CPT1C catalytically depalmitoylates
GluA1 in the ER prior to transport to the GA. Intriguingly,
in contrast with the apparent necessity for CPT1C catalytic
activity necessity, the hydrolase activity of a monoacylglycerol
lipase, ABHD6, was not required for its effects on AMPARs
(Wei et al., 2016).
Apart from their physiological role, numerous studies have
implicated AMPARs in neurological conditions (Cull-Candy
et al., 2006; Zarate and Manji, 2008; Chang et al., 2012) and
the implication of CPT1C in alterations that affect neurons
and glia has also been reported (Cirillo et al., 2014; Rinaldi
et al., 2015). Besides, AMPAR physiology seems to be altered
in normal ageing (Henley and Wilkinson, 2013), one of the
most challenging aspects of neuroscience research. The decline
in normal intellectual capabilities associated with ageing is
related in part to a reduced synaptic plasticity arising from
changes in postsynaptic membrane constituents, such as
AMPAR number and function. Certainly, aberrant AMPAR
trafficking and consequent abnormal changes in synapses are
a core feature in age-dependent cognitive decline (Henley
and Wilkinson, 2013). It has been previously described that
synaptic transmission is diminished in CPT1C KO pyramidal
HPNs (Fadó et al., 2015). In agreement with the already
described role of CPT1C in regulating AMPAR surface
expression, we have demonstrated that somatic AMPARs
in HPNs are also diminished in CPT1C KO animals,
which would account for the lower content of AMPARs at
the synaptic level reported previously (Fadó et al., 2015).
Interestingly there is a decline in CPT1C expression with
age (Carrasco et al., 2013) and since AMPAR trafficking
is favored by CPT1C (Gratacòs-Batlle et al., 2015) and the
receptor levels are also stabilized by this protein (Fadó
et al., 2015), this gradual decrease in expression of CPT1C
might compromise the normal synaptic function. Thus,
CPT1C presents itself as a part of the normal AMPAR
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cell biology and lack of this protein might be associated
with aging-related problems although this idea has not been
tested.
In summary, the work performed on this article sheds
light on the regulation of AMPAR function by CPT1C, which
modulates AMPAR trafficking by a putative depalmitoylating
mechanism.
CONCLUSION
Our results show for the first time that CPT1C possesses
a depalmitoylating catalytic activity on GluA1 subunit of
AMPARs. Based on in silico homology modeling of CPT1C
structure, we have identified a catalytic triad also present in
other PTE proteins. The histidine 470 from this catalytic triad of
CPT1C seems to be crucial in this enzymatic activity. Mutation of
His470 for an alanine abolishes both depalmitoylating activity on
GluA1 and CPT1C-mediated AMPAR trafficking enhancement
in cell lines and hippocampal neuronal cultures.
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